19 Oct 2010 . Tuesday, Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly & Co. (LLY) and Alkermes , Inc. (ALKS) said the U.S. Food and Drug Administration has .

20 Oct 2010 . Bydureon is a long-acting version of Amylin's popular diabetes medication Byetta . Both products were co-developed with Eli Lilly & Co. .

16 Jun 2010 . Mixed Results for Bydureon-The co-developers of type II diabetes candidate Bydureon (exenatide once weekly), announced mixed results from .

3 Mar 2011 . Well the results are in. In the sixth study of its kind pitting diabetes type 2 therapies in observation, Bydureon and Victoza went head to .

8 Feb 2011 . Today, the FDA announced that Eli Lilly's extended-release diabetes drug Bydureon wouldn't yet be authorized. Byetta is a drug that has been .

12 Jan 2011 . Bydureon is a new formulation of Byetta (scientific name: exenatide) that is being developed by Amylin and Lilly pharmaceuticals. .

20 Oct 2010 . Amylin Pharmaceuticals (Nasdaq: AMLN) received a disappointment yesterday, when the increasingly risk-averse US Food and Drug Administration .

21 Oct 2010 . Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has .

20 Oct 2010 . Amylin Pharmaceuticals Inc., Eli Lilly & Co. and Alkermes .

3 Mar 2011 . Eli Lilly, Amylin and Alkermes reported Thursday that in a late-stage head-to- head study, their experimental drug Bydureon (extended-release .

3 Mar 2011 . Eli Lilly ($LLY), Amylin ($AMLN) and Alkermes ($ALKS) have a .

22 Oct 2010 . Amylin Pharmaceuticals, Inc., Eli Lilly and Company and .

20 Oct 2010 . Bad news for Eli Lilly could be good news for Novo Nordisk. Now that FDA has asked for more research on Bydureon, the long-acting form of .

20 Oct 2010 . By now, you know that the FDA issued a complete respnse letter to Amylin, Lilly and Alkermes late yesterday that refused to approve their .

26 Jun 2010 . Safety data from the DURATION-1, -2 and -3 trials involving patients on either BYDUREON or pooled data from comparator groups including .

15 Nov 2010 . When biotech firms get bad news from the FDA, the fallout can have a dramatic impact on everyone from the CEO to the bench scientists.

23 Oct 2010 . The firm's partners on Bydureon also got hit, with shares of Alkermes Inc. ( NASDAQ:ALKS) falling $3.75, or 26 percent, to close at $10.75 .

6 Aug 2010 . The biotech could be the best trade of the three companies .

23 Apr 2010 . The companies are seeking to get Bydureon approved for the treatment of type II diabetes. In mid-March, the FDA had issued a complete .

20 Oct 2010 . The FDA has requested more studies on Bydureon before it approves the extended- release diabetes drug. This leaves Eli Lilly in a tough spot.

3 Mar 2011 . A new drug being tested to treat diabetes, Bydureon, was failed to show better performance than existing treatments on the market.

20 Oct 2010 . In a stunner, Amylin, Alkermes and Eli Lilly have been handed another major setback in their long quest to get the new, once-weekly diabetes .

20 Oct 2010 . The FDA's request will delay a potential launch of Bydureon by 18 months or more , and the increasing conservatism of regulators lessens the .

4 Mar 2011 . Amylin and Lilly may have overplayed their hand when they put their experimental once-weekly formulation of exenatide, a synthetic drug .

6 May 2010 . BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 .

15 Mar 2010 . Bydureon is a once weekly form of Byetta, an increasingly popular diabetes medication. It has a variety of effects that make it a useful .

3 Mar 2011 . Study compared Bydureon with Novo's Victoza * Bydureon failed .

4 Mar 2011 . Bydureon, an experimental Type 2 diabetes drug from Amylin, Eli Lilly and Alkermes, failed to outperform Novo Nordisk's Victoza in a recent .

20 Oct 2010 . Amylin Pharmaceuticals Inc. , Eli Lilly & Co. and Alkermes Inc . dropped in trading after they were rebuffed a second time in a bid to gain .

21 Oct 2010 . Eli Lilly: Confident That Bydureon Will Eventually Be Approved from Analyst Wire provided by Find Articles at BNET.

3 Mar 2011 . Amylin Pharmaceuticals Inc. and Alkermes Inc. plunged after the companies' diabetes drug Bydureon didn't control the disease better than .

3 Mar 2011 . A new drug being tested to treat diabetes , Bydureon, was failed to show better performance than existing treatments on the market.

16 Jun 2010 . Amylin Pharmaceuticals said its once-a-week injectable Type 2 diabetes drug Bydureon was more effective than rival Januvia and showed .

19 Oct 2010 . But that's just what happened last March when the FDA initially rejected Amylin Pharmaceuticals' (Nasdaq: AMLN) Bydureon. .

20 Oct 2010 . The bid to get Byetta (exenatide) once-weekly version for .

20 Oct 2010 . Bydureon makers Amylin Pharmaceuticals Inc. and Eli Lilly and Co. said that they will submit the new studies required by the FDA by the end .

30 Nov 2010 . What Bydureon is good for . Bydureon changes prices on stock . had initially expected the FDA to rule on Bydureon earlier this year. .

3 Mar 2011 . INDIANAPOLIS (AP) -- Drugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc . said Thursday that their potential diabetes treatment .

FDA's Decision to Reconsider 'Bydureon' – Another Chance for Diabetes Drug After rejecting the approval application of diabetes drug 'Bydureon'

29 Jul 2010 . Washington, DC : A recent observational study has found that Byetta carries no greater risk for acute pancreatitis than other Type 2 .

26 Jan 2011 . According to Mark Schoenebaum, the analyst at ISI Group, Amylin Pharmaceuticals has written permission from the Food and Drug Administration .

If approved this LAR will be marketed under the tradename, Bydureon. Bydureon is tested in a Phase III clinical study program called DURATION. .

23 Nov 2010 . Though it has been submitted to the FDA for endorsement, Bydureon is not yet ok for the US Market. The FDA has stated that they will not .

20 Oct 2010 . TradingMarkets News for Eli Lilly/Amylin: FDA delay for antidiabetic Bydureon leaves Novo's Victoza on top.

20 Oct 2010 . Going into the decision, investors figured there was a decent chance that the FDA would require additional clinical trials, which could have .

20 Oct 2010 . NEW YORK (Reuters) - Amylin Pharmaceuticals' shares lost nearly half their value on Wednesday, after U.S. regulators declined to approve the .

by JL Leahy

3 Mar 2011 . Drugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said that their potential diabetes treatment Bydureon proved inferior to Novo .

27 Jan 2011 . Shares are rebounding but Bydureon has a long way to go before it can be sold in US. Market success is questionable.

6 May 2010 . BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 .

Sitemap